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Structural magnetic resonance imaging (MRI) is the most frequently used method to 34 
investigate brain volume alterations in neuropsychiatric disease.  Previous meta-35 
analyses have typically focused on a single diagnosis, thereby precluding 36 
transdiagnostic comparisons. 37 
 38 
Methods and analysis 39 
We will include all structural MRI studies of adults that report brain volumes for 40 
participants from at least two of the following diagnostic groups: healthy controls, 41 
schizophrenia, schizoaffective disorder, delusional disorder, psychotic depression, 42 
clinical high risk for psychosis, schizotypal personality disorder, psychosis unspecified, 43 
bipolar disorder, autism spectrum disorder, major depressive disorder, attention deficit 44 
hyperactivity disorder, obsessive compulsive disorder, posttraumatic stress disorder, 45 
emotionally unstable personality disorder, 22q11 deletion syndrome, generalised 46 
anxiety disorder, social anxiety disorder, panic disorder, mixed anxiety and 47 
depression. Network meta-analysis will be used to synthesise eligible studies. The 48 
primary analysis will examine standardised mean difference in average volume, a 49 
secondary analysis will examine differences in variability of volumes. 50 
 51 
Discussion 52 
This network meta-analysis will provide a transdiagnostic integration of structural 53 
neuroimaging studies, providing researchers with a valuable summary of a large 54 
literature. 55 
 56 
PROSPERO Registration number: 221143 57 
 58 





 A wide range of neuropsychiatric disorders have been associated with alterations in 62 
regional brain volumes.1–3 Understanding whether regional patterns of structural 63 
abnormalities differ between disorders as opposed to representing a more general 64 
transdiagnostic disease process has major relevance for understanding the 65 
pathophysiology of neuropsychiatric disease.  66 
 67 
In addition to studying differences in the mean size of regional brain volumes, recent 68 
studies have highlighted that the variability of regional volume size also differs 69 
between healthy controls and individuals with psychiatric disorders.2,3 In some 70 
disorders, relatively homogenous volumetric changes to specific brain regions are 71 
observed, whereas other regions display more heterogenous differences, suggesting 72 
that structural alterations may only be present within certain subgroups of the 73 
diagnostic category. 74 
 75 
Meta-analysis has frequently been used in attempts to synthesise findings from the 76 
large number of studies of brain volumes. These analyses, however, typically only 77 
examine a single disorder.2,3 Network meta-analysis is an approach that is generally 78 
used for the comparison of efficacy across multiple health interventions, but can also 79 
be used to allow for the coherent synthesis of structural imaging studies across 80 
multiple disorders. Previous transdiagnostic meta-analyses have occasionally been 81 
reported. However, these meta-analyses either studied a restricted range of 82 
diagnoses;4 or used an activation likelihood estimate approach, which does not allow 83 
for quantification of effect sizes and so preclude determination of whether one disorder 84 
displays a regional volumetric alteration greater in magnitude than another.1  85 
 86 
In the current protocol we describe a network meta-analysis of structural MRI studies 87 
across a wide range of neuropsychiatric disorders. The primary objective of the study 88 
is to quantify patterns of similarity and differences between disorders in terms of 89 
regional brain volumes. The secondary objective is to examine how patterns of 90 
variability of brain volumes differ across neuropsychiatric diagnoses. 91 
  92 
 
 
METHODS AND ANALYSIS 93 
 94 
Types of studies 95 
All relevant published observational studies that use MRI to compare brain volumes 96 
in one neuropsychiatric disorder to another, or to controls will be identified by 97 
searching the relevant international scientific literature. 98 
 99 
Types of Participants 100 
The eligible population consists of individuals age 18 and over, of both sexes, with 101 
established diagnoses of any of the following disorders: schizophrenia, schizoaffective 102 
disorder, delusional disorder, psychotic depression, clinical high risk for psychosis, 103 
schizotypal personality disorder, psychosis unspecified, bipolar disorder, autism 104 
spectrum disorder, major depressive disorder, attention deficit hyperactivity disorder, 105 
obsessive compulsive disorder, posttraumatic stress disorder, emotionally unstable 106 
personality disorder, 22q11 deletion syndrome, generalised anxiety disorder, social 107 
anxiety disorder, panic disorder, mixed anxiety and depression. In addition, data from 108 
control groups will be extracted. These diagnoses encompass the vast majority of 109 
neuropsychiatric disorders in terms of lifetime prevalence, with the exception of 110 
substance use disorders.5 We have chosen not to include substance use disorders 111 
due to the difficulties in disambiguating the brain changes associated with the 112 
pathophysiology of addiction, and those that result from the direct effects of substance 113 
use. 114 
 115 
Diagnoses should have been made using standardised diagnostic criteria such as the 116 
Research Diagnostic Criteria, Diagnostic and Statistical Manual of Mental Disorders, 117 
Third Edition (DSM-III), DSM-III-R, DSM-IV, DSM-5, International Classification of 118 
Disease, 10th Revision (ICD-10), ICD-11 or the comprehensive assessment of At-Risk 119 
Mental States.6 Study arms explicitly examining participants with comorbid psychiatric 120 
or physical health disorders will not be included. Uncertainty regarding study eligibility 121 
will be decided by discussion between authors. 122 
 123 
Outcome Measures 124 
For each study we aim to collect the mean and standard deviation of volumetric (in 125 
mm3 or cm3) or thickness (mm or cm) measurements for global and/or regional brain 126 
 
 
structures. Brain volumes examined will include: whole brain, whole brain white 127 
matter, whole brain gray matter, whole brain cerebrospinal fluid, amygdala, anterior 128 
cingulate cortex, accumbens, caudate, cerebellum, corpus callosum, frontal lobe, 129 
hippocampus, insula, lateral ventricle, pallidum, parahippocampal gyrus, parietal lobe, 130 
putamen, temporal lobe, thalamus, and third ventricle. If reported separately, values 131 
will be extracted for both left and right hemispheres. 132 
 133 
If only subregions of the above regions are reported (e.g. frontal pole and medial 134 
frontal cortex are reported, but no overall value for frontal lobe is reported), then all 135 
subregions for the region in question will be combined. For volume measurements the 136 
overall mean volume measure will be obtained by summing the subregion volumes, 137 
with standard deviations being calculated according to standard propagation of 138 
uncertainty formula with the between region correlation assumed to be 0.7. For 139 
thickness measurements overall mean volume measure will be obtained by averaging 140 
the subregion thickness values, with standard deviations being calculated according 141 
to standard propagation of uncertainty formula, with the between region correlation 142 
assumed to be 0.7, and subregions weighted according to their estimated volume as 143 
reported within the Desikan-Killany atlas 7. 144 
 145 
If both normalised and non-normalised volumes are reported, non-normalised 146 
volumes are preferred. If gray and white matter values are reported separately for a 147 
region, gray matter values are preferred. If both volume and thickness measurements 148 
(in mm or cm) are reported, volume measurements are preferred.  149 
 150 
Search Strategy 151 
The search strategy will include terms related to the study population, study type, and 152 
main outcome. This search will extract studies from the following databases: Embase 153 
(Ovid interface), MEDLINE (Ovid interface) and PsycINFO (Ovid interface).  Hand-154 
searching will also be performed to supplement electronic database searches, this will 155 
involve reviewing the reference lists of studies meeting our eligibility criteria.   156 
 157 
Search term: 158 
(("magnetic resonance imaging" or MRI) and volume and (schizophren* or psychosis 159 
or schizoaffective or delusional or bipolar or depression or depressive or affective or 160 
 
 
autism or ASD or ADHD or "attention deficit" or anxiety or OCD or "obsessive 161 
compulsive" or PTSD or posttraumatic or 22q or velocardiofacial or "emotionally 162 
unstable" or "borderline personality")).ab,kw,ti. 163 
 164 
Data extraction 165 
Extracted information will be as follows: number of participants in each group, mean 166 
age, gender (% male), ethnicity (% black, white, other), psychiatric diagnosis including 167 
any comorbidities, age at illness onset, illness duration, psychotropic usage, method 168 
of  measurement (volume vs thickness, automated vs manual), magnetic field 169 
strength, units of measurement, mean ± standard deviation (SD) of regions stated 170 
above. 171 
 172 
Seven researchers will select the studies and extract the relevant information (XG, LV, 173 
TAH, CC, RM, GW) into a shared google sheet. If there is evidence of overlapping 174 
samples between studies, the study with the larger sample size will be used. 175 
 176 
Data Synthesis 177 
A qualitative synthesis of the collected data will also be presented. This will include 178 
summary tables showing the characteristics of the study population - demographics, 179 
diagnosis, age at illness onset, illness duration, medication use and duration of 180 
pharmacological treatment, and a PRISMA flowchart. 181 
 182 
Pairwise meta-analyses 183 
The principal summary measure will be the standardised mean difference (Hedges’ g) 184 
between diagnostic groups for the volumes of different brain regions.8  185 
 186 
The secondary summary measure will be the coefficient of variation ratio (CVR). This 187 
is a measure of  how variability differs between two groups while controlling for mean, 188 
and has been used in pervious meta-analyses of brain structure to identify if there is 189 
evidence of subgroup phenomena within psychiatric disorders.2,3,9 190 
 191 
We will perform direct meta-analyses for all pairs with >/=3 studies to obtain mean 192 
brain volume differences with their accompanying 95% confidence intervals using a 193 
random effects model. Analyses will be carried out in the statistical programming 194 
 
 
language R (version 3.5.1) using ‘metafor’ (version 2.1-0).10 Visual inspection of the 195 
forest plots will be used to investigate the degree of statistical heterogeneity, alongside 196 
monitoring of τ (the estimated standard deviation of random effects) and the I2 197 
statistic. An I2 of less than 25% will be deemed to correspond to low heterogeneity, 198 
25-75% medium heterogeneity, and greater than 75% high heterogeneity. To help 199 
visualize and assess the extent of heterogeneity we will also include prediction 200 
intervals in all forest-plots. 201 
 202 
Small study effects and publication bias will be assessed for each pairwise comparison 203 
by visual inspection of the contour-enhanced funnel plot and by performing Egger’s 204 
test of the intercept for meta-analyses comprising at least 10 studies.11 205 
 206 
Assessment of the transitivity assumption 207 
In an attempt to ensure transitivity in the network, we will exclude studies examining 208 
paediatric patients, and exclude studies in which physical and psychiatric 209 
comorbidities are specifically studied. 210 
 211 
Potential effect modifiers include age, gender, and ethnicity. As such, we will examine 212 
if age, gender (% male) and ethnicity (% white) of participants is similarly distributed 213 
across the different diagnoses and health control populations. 214 
 215 
Network Meta-analyses 216 
If there is sufficient similarity between studies in terms of age, gender and ethnicity, 217 
we will conduct a random-effects network meta-analysis to synthesise our data. 218 
Network plots will be generated using the ‘netgraph’ function from the package 219 
‘netmeta’,12 with each node representing a specific disorder, the size of the node being 220 
proportional to the number of studies used, and the thickness of the lines (edges) 221 
between nodes being proportional to the number of pairwise comparisons.  222 
 223 
We will use a frequentist approach to network meta-analysis using ‘netmeta’ in R 224 
(version 1.0-1). In order to allow for comparison across different scanners and 225 
measurement approaches we will express volume differences between disorders as 226 




We will produce forest plots using ‘ggplot2’ (version 2.2.1), where the control group 229 
will be used as the reference. League tables will be created to display the relative 230 
degree of volume alteration for the various diagnostic groups using the ‘netleague’ 231 
function. 232 
 233 
For each brain region, we will use the P-scores to rank diagnostic groups based on 234 
the corresponding degree of volume alteration. This will be done using the ‘netrank’ 235 
function. This method will allow us to rank the diagnostic groups on a continuous 0 to 236 
1 scale for each outcome of interest: a higher P-score indicates greater degree of 237 
volume alteration.  To summarise results across brain regions and disorders in a single 238 
diagram we will produce a ‘Kilim plot’.13 239 
 240 
Assessments of heterogeneity and inconsistency  241 
Heterogeneity of each network will be assessed by monitoring of τ and by plotting the 242 
prediction intervals for all comparisons versus placebo. Consistency of each network 243 
(i.e. the agreement between direct and indirect evidence) will be evaluated using a 244 
global method (Q statistic) as well as a local method (back-calculation method using 245 
the ‘netsplit’ function).14  246 
 247 
Sensitivity Analyses 248 
The ENIGMA consortium has published several large scale syntheses of 249 
neuroimaging data.15,16 It is not straightforward to determine the overlap between 250 
these studies and previously published work, as a result a sensitivity analysis will be 251 
ran both including and excluding ENIGMA studies. 252 
 253 
Meta-regression analyses 254 
In addition to neuropsychiatric disorders, multiple other genetic and environmental 255 
factors also influence brain volumes. These include ageing and the use of 256 
psychotropic medications. We will therefore perform a meta-regression analysis to 257 
examine the relationship between study-level means of participant characteristics 258 
(gender, age, ethnicity (% white), illness duration, medication use) and differences in 259 
brain volumes, for each diagnosis vs. a control population. Meta-regressions will be 260 
 
 
performed using the ‘metafor’ function in R statistical software (version 3.5.3) and plots 261 
will be generated using ‘ggplot2’. We will only perform this analysis for diagnoses 262 
compared with controls in at least five studies. 263 
 264 
Risk of Bias 265 
Two independent reviewers will assess the quality of each study using a modified 266 
version of the Newcastle-Ottawa Scale for case control studies in which the exposure 267 
category is not considered due to its lack of relevance for imaging studies. This is the 268 
most appropriate scale given that observational studies are expected to predominate. 269 
Each study can receive a score from zero (low quality, high risk of bias) to six stars 270 
(high quality, low risk of bias). A threshold of >/= 4 stars will be used to designate a 271 
high-quality study.  272 
 273 
The ‘Confidence in Network Meta-Analysis’ (CINeMA)  application will be employed to 274 
evaluate the credibility of findings from network meta-analysis.14,17 As part of the 275 
CINeMA evaluation process, a risk of bias assessment is required for each study with 276 
each study categorised as at low, unclear, or high risk of bias, we will use the same 277 
threshold of >/= 4 stars to classify studies as being at low or high risk of bias.  278 
 279 
Discussion 280 
Structural brain abnormalities in neuropsychiatric disease have been studied in 281 
increasing depth over the past half century, with the number of studies increasing 282 
dramatically following the advent of MRI. While meta-analyses of individual disorders 283 
aid in the synthesis of this vast body of research, understanding how findings 284 
regarding one disorder relate to another remains a major challenge. In recent years 285 
studies have undertaken transdiagnostic attempts, but these involve smaller numbers 286 
of participants than a meta-analytic approach allows for or do not encompass as broad 287 
a range of disorders. This network meta-analysis provides a powerful approach to 288 
deriving a coherent understanding of brain abnormalities across neuropsychiatric 289 
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